Pall Life Sciences to Introduce Continuous Bioprocessing with Single-Use Technologies

PORT WASHINGTON, N.Y.–(BUSINESS WIRE)– At next week’s first annual Biotech Week Boston (October 4-7, 2016),
Pall Corporation, a global leader in filtration, separation and
purification, will officially launch new production-scale technologies
and preview upcoming technologies that enable fully continuous
biopharmaceutical processing using single-use formats. These solutions
will be formally introduced at the BioProcess International Conference &
Exhibition (BPI), October 4 – 7, 2016 at the Boston Convention and
Exhibition Center (BCEC), Booth #521.

As manufacturers of biotherapies seek to incorporate continuous
technologies in production to improve efficiency over batch methods, and
to enable process intensification, Pall is forging ahead by offering
biopharmaceutical companies an “end-to-end” continuous processing option
with integrated single-use technologies. Single-use systems enable
manufacturers to reduce costs by eliminating cleaning and validation
requirements, as well as hardware infrastructure.

Last year Pall introduced the Cadence™ BioSMB PD System, the first
disposable flow path, continuous multi-column chromatography system that
is scalable from laboratory process development to GMP manufacturing.
Earlier this year, Pall introduced the Cadence Acoustic Separator (CAS)¹,
a groundbreaking invention that incorporates acoustic wave separation
(AWS) technology to continuously harvest biologic drug substances from
cell culture processes. At BPI Pall will continue to advance its
pipeline of products that enable continuous manufacturing by launching
production-scale continuous chromatography solutions, a new single-use
stirred tank bioreactor, single-use sterile genderless connectors, and
other equipment and materials. In addition, Pall will feature filtration
technology for consistent and robust small virus retention.

“At Pall we are helping the industry move continuous bioprocessing from
theory to reality,” said Michael Egholm, Ph.D., VP and General Manager,
Pall BioPharmaceuticals. “Our continuous-ready products and integration
expertise help manufacturers of biotherapeutics achieve high-quality
products with smaller production footprints and shorter lead times.”

Egholm will introduce Steve Wozniak, Apple Co-Founder as the keynote
speaker for the conference program at Biotech Week Boston on Friday,
October 7, at 9:15am. Wozniak’s presentation will cover innovation and
customer centricity. (Please find details below)

As the Presidential Sponsor of Biotech Week Boston, Pall also will host,
present and participate in a number of activities at the BCEC, including
the following:

• Tuesday, Oct. 4 – 9:00am – 5:00pm
  Symposium
  on Continuous Processing – sponsored by Pall Life Sciences
  Topics
  will include GMP implementation, regulatory and quality
  considerations, and making the business case for continuous
  processing. The symposium will include case studies presented by
  Merck, Merrimack Pharmaceuticals, CMC Biologics, Biogen, Just
  Therapeutics and others.

  Pall speakers at this daylong
  workshop will include:

  • Marc
    Bisschops, Ph.D., Principal Scientist, , Pall Life Sciences,
    Holland
  • Mark
    Schofield, Ph.D., Principal R&D Engineer, Pall Life Sciences
  • Peter
    Levison, Senior Marketing Director – Downstream Processing,
    Pall Life Sciences
• Tuesday, Oct. 4 – 7:30pm – 10:30pm
  BPI « Bio
  Brew » Networking Event at the Harpoon Brewery
  Pall
  will co-sponsor this event with Kaneka Corporation. Pall and Kaneka
  recently entered into a collaborative agreement for Pall to supply
  Kaneka’s Protein A chromatography resin (KANEKA KanCapA). A shuttle
  outside the BCEC will be available to transport attendees
  (pre-registration is required).
• Wednesday, Oct. 5 – 9:30am – 10:30am
  Pall Presentation
  “An
  update on significant technology advances enabling integrated
  continuous bioprocessing,” presented by Martin
  Smith, Ph.D., Chief Technology Officer, Pall Corporation and Michael
  Egholm, Ph.D., VP and General Manager, Pall Life Sciences.
• Wednesday, Oct. 5 – 11:30am – 12:00pm
  Pall Presentation
  “End-to-End
  Integrated Continuous BioProcessing Platform for Biologics
  Manufacturing,” presented by Engin
  Ayturk, Ph.D., Senior Manager R&D, BioPharm Applications R&D, Pall
  Corporation.
• Friday, Oct. 7 – 9:15am – 10:15am
  Keynote address by
  Apple Co-Founder Steve Wozniak
  Topic: Innovation &
  Customer Centricity. Steve will be introduced by Pall’s Michael
  Egholm.
• Friday, Oct. 7 – 10:15am (Pall’s Lounge, Booth #621)
  Steve
  Wozniak Meet & Greet
  Steve will be available for a brief
  period to meet with expo attendees.

In addition to finding Pall representatives at the company’s main booth
(#521), show and conference attendees can also enjoy free refreshments
at Pall’s neighboring lounge, Booth #621 and visit Booth #1355 for
Pall’s technologies and services dedicated to cell and gene therapy, and
vaccines. A highlight of the Cell and Gene Therapy sessions at the BPI
conference will be “Achieving Large-Scale GMP Production of Adenovirus
in the iCellis 500 Fixed-Bed Bioreactor.” This presentation by FinVector
Vision Therapies will detail the use of the Pall iCELLis single-use
perfusion bioreactor system. It will take place on Wednesday, October 5,
at 2:15pm in the Gene Therapy Development & Production –
Manufacturing Strategies and Solutions for Gene Therapies track.

About Pall Corporation

Pall Corporation is a filtration, separation and purification leader
providing solutions to meet the critical fluid management needs of
customers across the broad spectrum of life sciences and industry. Pall
works with customers to advance health, safety and environmentally
responsible technologies. The Company’s engineered products enable
process and product innovation and minimize emissions and waste. Pall
Corporation serves customers worldwide. For more information visit www.pall.com.

Or follow us on social media:

Google+
YouTube
LinkedIn
Twitter
Facebook

¹ On June 15, 2015, Pall announced an exclusive licensing
agreement with FloDesign Sonics for acoustic wave separation, a
disruptive technology for cell culture clarification for both fed-batch
and perfusion applications.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160928006492/en/